SEC Form 4 · accession 0001662252-16-000303
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger D. Kornberg
Director
Period of report
Dec 20, 2016
Accepted (ET)
Dec 23, 2016 · 2:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $10.23 | Dec 20, 2016 | A | 3,030 | A | Dec 20, 2016 | Feb 28, 2026 | Common Stock | 3,030 | 3,030 | D |
| Stock OptionF2 | $3.50 | Dec 20, 2016 | A | 21,970 | A | Dec 20, 2016 | Dec 20, 2026 | Common Stock | 21,970 | 25,000 | D |
Explanation of responses
- F1On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The grant had been approved and was part of an agreement (but not issued) on the date of the Reporting Owner began service as a director of the Issuer. Under the agreement and grant, the Reporting Owner has the right to purchase 3,030 shares of common stock of the Issuer under the Plan at an exercise price based on the adjusted price of the stock on the date of his appointment to the board.
- F2On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 21,970 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50.